By Dennis Thompson HealthDay ReporterTHURSDAY, April 9, 2026 (HealthDay News) — Prompt treatment with a fecal transplant can ...
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
Vedanta Biosciences is a late clinical-stage biopharmaceutical company developing a new category of microbiome-based oral therapies for gastrointestinal diseases. Vedanta's lead program, VE303, is ...
A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...
Researchers say the reduction was influenced by the combined effects of changes in infection prevention and control, ...
Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...
New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge. A new report suggests microbiota-based ...
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has completed ...
A study of hospitals and long-term care facilities in Louisville, Kentucky, found low rates of Clostridioides difficile testing in patients with new-onset diarrhea who are frequently infected. CDI is ...
The role of food in Clostridioides difficile transmission chains still needs to be clarified, according to a study. Clostridioides difficile infection (CDI) is a notable cause of infectious diarrhea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results